PHSSR Saudi Arabia 2025

16 Sustainability and Resilience in the Saudi Arabian Health System The Partnership for Health System Sustainability and Resilience DOMAIN 3 WORKFORCE 3A Establish mechanisms to forecast future healthcare workforce supply and demand, with projections taken into account in national workforce training strategies. 3B Design and implement a mechanism for the routine evaluation of health workforce performance, productivity and wellbeing to inform interventions for their improvement. 3C Develop and enforce a national health competency framework aligned with the plans to implement a value-based health system. 3D Ensure prioritisation of the well-being and psychological safety of healthcare workers, involving service providers, regulator and accreditation organisations and in the health ecosystem in general to reduce burnout and staff turnover. 3E Meet targets for the number of Saudi Arabian nationals in the health workforce, especially in the nursing profession. 3F Incentivise services to rural and underserved areas to address disparities in access to care. 3G Expand and diversify the healthcare workforce by investing in education and training programmes to meet the needs of a growing population. DOMAIN 4 MEDICINES AND TECHNOLOGY 4A Establish public –private partnerships (PPPs) in medicines and health technologies in order to pool resources and expertise, thus improving access, affordability and innovation. 4B Increase the digital maturity of health service providers, especially in relation to clinical documentation using electronic medical record (EMR) systems, disease registries and national formularies to reduce medication errors, improve patient safety and enhance the e fficiency of the healthcare system. 4C Enhance national stockpiles of essential medicines, equipment and supplies to ensure the timely and e fficient distribution of medicines and health technologies, reduce stockouts and improve accessibility. 4D Accelerate health technology assessment (HTA) capacity to determine the value and effectiveness of new health technologies and medicines, enabling evidence-based decision-making and resource allocation. 4E Encourage research and development (R&D) in medicines and health technologies to foster innovation and development to address the evolving healthcare needs of the population. 4F Foster the use of cost-effectiveness analysis in the evaluation of medicines and health technologies to improve resource allocation and ensure value for money. 4G Promote cost-effective use of generic medicines and biosimilars to improve affordability and accessibility, without compromising quality.